Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 14, 2025Scientia PharmaceuticaOpen Access

Development and Optimisation of Docetaxel-Loaded Polymeric Nanoparticles for Oral Chemotherapy in Breast Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

DWDivya WaliSNShivakumar H. NanjappaAKAvichal Kumar

Discussion

Loading...

Member takes

Overview

Nanoparticle formulation demonstrates lower IC50 and improved safety in breast cancer, indicating potential for oral chemotherapy.

Key Points

  • In vitro assays showed a 39.52 µM IC50 for optimized nanoparticles versus 60.81 µM for Docetaxel, highlighting superior anticancer efficacy.
  • The nanoparticles were characterized by zeta potential and scanning electron microscopy, demonstrating promising characteristics.
  • Polymeric nanoparticles exhibit enhanced drug release and entrapment efficiency, suggesting potential for targeted therapy.
  • Safety assays indicated significantly lower haemolytic potential for nanoparticles compared to conventional Docetaxel.

Cite This Study

Wali et al. (2025) studied this question.

synapsesocial.com/papers/692519a7c0ce034ddc353fc1https://doi.org/10.3390/scipharm93040058
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Quality by design-based development and optimization of polymeric nanoparticles for co-administration of docetaxel and curcumin: In vitro characterization and preclinical evaluation2026
  2. 2Development and evaluation of docetaxel-hesperidin loaded nanoformulation for the treatment of breast cancer2026
  3. 3Formulation And Optimization Of Lipid-Polymer Hybrid Nanoparticles For Targeted Delivery Of Docetaxel: A Novel Approach In Cancer Therapy2025 · 1 citations
  4. 4Development of docetaxel-loaded (Soluplus®–PF108) mixed micelles vacuum foam-dried product for improved stability and melanoma treatment by QbD approach2024 · 5 citations
  5. 5Minimizing Cytotoxic Effects on Normal Cells: Enhanced Targeted Delivery of Docetaxel via PCL-PEG-PCL Nanocarriers in Breast Cancer Treatment2025